294 related articles for article (PubMed ID: 28342366)
1. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, molecular docking, dynamic simulation and pharmacological characterization of potent multifunctional agent (dual GPR40-PPARγ agonist) for the treatment of experimental type 2 diabetes.
Hidalgo-Figueroa S; Rodríguez-Luévano A; Almanza-Pérez JC; Giacoman-Martínez A; Ortiz-Andrade R; León-Rivera I; Navarrete-Vázquez G
Eur J Pharmacol; 2021 Sep; 907():174244. PubMed ID: 34116041
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and in Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids.
Colín-Lozano B; Estrada-Soto S; Chávez-Silva F; Gutiérrez-Hernández A; Cerón-Romero L; Giacoman-Martínez A; Almanza-Pérez JC; Hernández-Núñez E; Wang Z; Xie X; Cappiello M; Balestri F; Mura U; Navarrete-Vazquez G
Molecules; 2018 Feb; 23(2):. PubMed ID: 29415496
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro and in silico studies of a PPARγ and GLUT-4 modulator with hypoglycemic effect.
Navarrete-Vázquez G; Torres-Gómez H; Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Medina-Franco JL; León-Rivera I; Alarcón-Aguilar FJ; Almanza-Pérez JC
Bioorg Med Chem Lett; 2014 Sep; 24(18):4575-4579. PubMed ID: 25131539
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
[TBL] [Abstract][Full Text] [Related]
7. Isolated mangiferin and naringenin exert antidiabetic effect via PPAR
Singh AK; Raj V; Keshari AK; Rai A; Kumar P; Rawat A; Maity B; Kumar D; Prakash A; De A; Samanta A; Bhattacharya B; Saha S
Chem Biol Interact; 2018 Jan; 280():33-44. PubMed ID: 29223569
[TBL] [Abstract][Full Text] [Related]
8. Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPARγ in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway.
Gandhi GR; Jothi G; Antony PJ; Balakrishna K; Paulraj MG; Ignacimuthu S; Stalin A; Al-Dhabi NA
Eur J Pharmacol; 2014 Dec; 745():201-16. PubMed ID: 25445038
[TBL] [Abstract][Full Text] [Related]
9. Insulin sensitization via partial agonism of PPARγ and glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway by embelin in type 2 diabetic rats.
Gandhi GR; Stalin A; Balakrishna K; Ignacimuthu S; Paulraj MG; Vishal R
Biochim Biophys Acta; 2013 Jan; 1830(1):2243-55. PubMed ID: 23104384
[TBL] [Abstract][Full Text] [Related]
10. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, in vitro, in vivo and in silico pharmacological characterization of antidiabetic N-Boc-l-tyrosine-based compounds.
Herrera-Rueda MÁ; Tlahuext H; Paoli P; Giacoman-Martínez A; Almanza-Pérez JC; Pérez-Sánchez H; Gutiérrez-Hernández A; Chávez-Silva F; Dominguez-Mendoza EA; Estrada-Soto S; Navarrete-Vazquez G
Biomed Pharmacother; 2018 Dec; 108():670-678. PubMed ID: 30245467
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
14. Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes.
Zhang X; Liu H; Sun B; Sun Y; Zhong W; Liu Y; Chen S; Ling H; Zhou L; Jing X; Qin Y; Xiao T; Sun T; Zhou H; Yang C
Sci Rep; 2016 Nov; 6():37323. PubMed ID: 27853282
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression.
Nazreen S; Alam MS; Hamid H; Yar MS; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai KK
Bioorg Med Chem Lett; 2014 Jul; 24(14):3034-42. PubMed ID: 24890090
[TBL] [Abstract][Full Text] [Related]
16. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
17. 4-Hydroxybenzoic Acid and
Rosiles-Alanis W; Zamilpa A; García-Macedo R; Zavala-Sánchez MA; Hidalgo-Figueroa S; Mora-Ramiro B; Román-Ramos R; Estrada-Soto SE; Almanza-Perez JC
J Med Food; 2022 Jun; 25(6):588-596. PubMed ID: 35708636
[TBL] [Abstract][Full Text] [Related]
18. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
[TBL] [Abstract][Full Text] [Related]
19. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR
BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736
[TBL] [Abstract][Full Text] [Related]
20. Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
Mourad AAE; Mourad MAE
Life Sci; 2020 Oct; 259():118270. PubMed ID: 32814067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
